Edition:
United States

Kangmei Pharmaceutical Co Ltd (600518.SS)

600518.SS on Shanghai Stock Exchange

21.60CNY
14 Dec 2017
Change (% chg)

¥-0.21 (-0.96%)
Prev Close
¥21.81
Open
¥21.79
Day's High
¥21.79
Day's Low
¥21.47
Volume
7,993,522
Avg. Vol
19,554,165
52-wk High
¥23.90
52-wk Low
¥16.95

Chart for

About

Kangmei Pharmaceutical Co., Ltd is a China-based company, principally engaged in the manufacture and sales of pharmaceutical products. The Company's principal products are Chinese medicines, including American ginseng, notoginseng powder, salvia powder, radix codonopsis pilosulae, maltiflower knotweed, angelica and lonicera... (more)

Overall

Beta: 0.83
Market Cap(Mil.): ¥107,888.50
Shares Outstanding(Mil.): 4,946.74
Dividend: 0.20
Yield (%): 0.94

Financials

  Industry Sector
P/E (TTM): -- 32.07 15.47
EPS (TTM): -- -- --
ROI: -- 15.07 33.71
ROE: -- 16.57 16.38

BRIEF-Kangmei Pharmaceutical in deal to invest 5 bln yuan in Guizhou

* SAYS IT SIGNS STRATEGIC AGREEMENT TO INVEST 5.0 BILLION YUAN ($756.06 million) IN GUIZHOU ON AREAS INCLUDING CHINESE MEDICINE RESEARCH, HEALTH BIG DATA Source text in Chinese: http://bit.ly/2Avc4TM Further company coverage: ($1 = 6.6132 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

Dec 06 2017

BRIEF-Kangmei Pharmaceutical's controlling shareholder issues 2017 second tranche exchangeable bonds worth 3 bln yuan

* Says its controlling shareholder issues 2017 second tranche non-public exchangeable bonds worth 3 billion yuan, with a term of three years

Dec 03 2017

BRIEF-Kangmei Pharmaceutical says controlling shareholder issues 2017 1st tranche non-public exchangeable bonds worth 2 bln yuan

* Says co's controlling shareholder, an industry investment firm, issued 2017 first tranche non-public exchangeable bonds worth 2 billion yuan, with term of 3 years

Nov 08 2017

BRIEF-Kangmei Pharmaceutical , BGI Genomics in strategic agreement

Oct 31 Kangmei Pharmaceutical Co Ltd , BGI Genomics Co LTd

Oct 31 2017

BRIEF-Kangmei Pharmaceutical issues 2017 third tranche mid-term bills worth 2 bln yuan

* Says it issued 2017 third tranche mid-term bills worth 2 billion yuan with a term of 5 years, and coupon rate of 5.47 percent

Sep 18 2017

BRIEF-Kangmei Pharmaceutical adopts new accounting policies

* Says it adopts new accounting policies regarding government subsidy, and non-current assets, disposal group and discontinued operations

Aug 29 2017

BRIEF-Kangmei Pharmaceutical unit plans two 80-pct-owned medical equipment JVs with partner

* Says its unit plans to invest totaling 16 million yuan to set up two medical equipment JVs with partner, and will own a 80 percent stake in JVs respectively

Aug 29 2017

BRIEF-Kangmei Pharmaceutical unit to buy medical sci-tech firm for 1.8 mln yuan

* Says its wholly owned pharma subsidiary plans to fully acquire a Hainan-based medical sci-tech firm for about 1.8 million yuan

Aug 29 2017

BRIEF-Kangmei Pharmaceutical's H1 net profit up 21.83 pct y/y

* Says H1 net profit up 21.83 percent y/y at 2.15 billion yuan ($324.87 million)

Aug 28 2017

BRIEF-Kangmei Pharma's controlling shareholder to issue up to 5.0 bln yuan exchangeable bonds

* Says controlling shareholder plans to issue up to 5.0 billion yuan ($744.08 million) exchangeable bonds

Aug 07 2017

Earnings vs. Estimates